David Shore, MD
Endocrinology, Diabetes & Metabolism · Lawrenceville, GANPI 1619065067
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.5%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Dexcom, Inc. at 52.1% of the total. 2025 is the largest year on record at $18,421, 7.6 times the $2,418 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 719 payments — averaging $115.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$43K
- Abbott$18K
- Ascensia Diabetes Care US Inc.$4K
- Corcept Therapeutics$3K
- Novo Nordisk$3K
- Amgen$2K
- plus $10K from 54 others
What the payments were for
- Consulting fees$12,60515%
- Speaking & faculty fees$45,89155%
- Travel & lodging$2,7123%
- Food & beverage$21,49226%
- Education$310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G6 TRANSMITTER$22,705
- DEXCOM G7 GSS (161)$19,536
- FREESTYLE LIBRE 3$15,954
- EVERSENSE E3 SENSOR KIT - RETAIL$3,459
- Korlym$2,670
- TEPEZZA$651
- t:slim X2 Insulin Pump with Control-IQ$601
- EVENITY$504
- Licart$500
- FLECTOR$500
- FreeStyle Libre Pro$483
- Ozempic$464
- RYBELSUS$456
- iLet Bionic Pancreas$430
- Omnipod$314
- INPEN SMART INSULIN DELIVERY SYSTEM$274
- TZIELD$246
- FARXIGA$228
- TWIIST$158
- UNITY DIABETES MANAGEMENT SYSTEM$153
How this compares
$82,731 in reported general payments places this provider in the 95th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 286 | $490,065 |
| MounjaroTirzepatide | 134 | $289,741 |
| JardianceEmpagliflozin | 194 | $257,068 |
| TrulicityDulaglutide | 95 | $210,880 |
| FarxigaDapagliflozin Propanediol | 96 | $127,524 |
| JanuviaSitagliptin Phosphate | 85 | $115,945 |
| Tresiba Flextouch U-100Insulin Degludec | 109 | $76,756 |
| Tresiba Flextouch U-200Insulin Degludec | 33 | $67,176 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 42 | $48,765 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $40,047 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 45 | $32,340 |
| TradjentaLinagliptin | 26 | $30,900 |
| Novolog FlexpenInsulin Aspart | 78 | $30,204 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 160 | $28,507 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 44 | $28,150 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $2,864 | $535,403336 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $542 | $519,881314 claims |
| Boehringer IngelheimJardiance, Tradjenta | $125 | $287,968220 claims |
| MerckJanuvia, Janumet | $28 | $130,38198 claims |
| AstraZenecaFarxiga | $688 | $127,52496 claims |
| AbbVieSynthroid | $207 | $18,327184 claims |
| Sanofi-aventis U.S. LLCLantus | $1,249 | $6,91927 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $171 | $6,373587 claims |
| PfizerLevoxyl | $20 | $1,34823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Lawrenceville
- Adeniyi OdugbesanLawrenceville$636K
- David ArkinLawrenceville$15K
- Aparna MahakalaLawrenceville$12K
- Bruce BodeAtlanta$1.5M
- David RobertsonAtlanta$1.4M
- Miguel MunozMarietta$476K
- Jason BernerJasper$457K
- Dawn Smiley-ByrdTaylorsville$385K
- Barry JohnsMacon$335K
- Jonathan OwnbyAtlanta$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.